Production (Stage)
ANI Pharmaceuticals, Inc.
ANIP
$57.79
$0.520.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.68M | -10.28M | -24.17M | -2.29M | 18.21M |
| Total Depreciation and Amortization | 22.89M | 22.60M | 15.75M | 14.70M | 14.69M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.91M | 11.54M | 9.34M | 9.51M | -4.40M |
| Change in Net Operating Assets | 1.33M | -8.01M | 11.55M | -4.51M | -10.23M |
| Cash from Operations | 34.99M | 15.86M | 12.47M | 17.41M | 18.27M |
| Capital Expenditure | -2.47M | -2.39M | -4.81M | -4.45M | -4.58M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 0.00 | 13.51M |
| Cash Acquisitions | -- | -8.20M | -393.08M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.37M | -86.00K | -631.00K | -- | -- |
| Cash from Investing | -19.85M | -10.68M | -398.52M | -4.45M | 8.93M |
| Total Debt Issued | -- | 0.00 | 641.25M | -- | -- |
| Total Debt Repaid | -2.03M | -156.00K | -294.38M | -750.00K | -750.00K |
| Issuance of Common Stock | 2.53M | 1.70M | 1.19M | 1.01M | 2.59M |
| Repurchase of Common Stock | -10.00M | -318.00K | -680.00K | -1.30M | -8.66M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -406.00K | -406.00K | -406.00K | -407.00K | -406.00K |
| Other Financing Activities | -- | -5.73M | -55.95M | 0.00 | -12.50M |
| Cash from Financing | -9.91M | -4.91M | 291.03M | -1.45M | -19.73M |
| Foreign Exchange rate Adjustments | -297.00K | -395.00K | -75.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.94M | -123.00K | -95.09M | 11.51M | 7.48M |